Eric Chavez
Psychiatry · San Diego, CANPI 1902813157
Payments from drug & device makers
Across 1,524 payments — averaging $10,181 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$3.3M
- Eli Lilly$3.2M
- Janssen Research & Development, LLC$2.1M
- AbbVie$1.3M
- Sage Therapeutics, LLC$1.2M
- Imbrium Therapeutics L.p.$823K
- plus $3.7M from 22 others
Across 43 payments — averaging $358.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Orexo US, Inc.$8K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$4K
- Supernus Pharmaceuticals, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Eli Lilly$750
What the payments were for
- Food & beverage$217100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 609 | $3,253,520 |
| Eli Lilly | 30 | $3,175,923 |
| Janssen Research & Development, LLC | 125 | $2,055,308 |
| AbbVie(2 entities) | 108 | $1,275,123 |
| Sage Therapeutics, LLC | 114 | $1,200,905 |
| Imbrium Therapeutics L.p. | 36 | $822,692 |
| Axsome Therapeutics, Inc. | 32 | $781,483 |
| Teva Pharmaceuticals USA, Inc. | 93 | $603,450 |
| Boehringer Ingelheim | 53 | $568,079 |
| Supernus Pharmaceuticals, Inc. | 60 | $424,682 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 13 | $405,632 |
| Merck | 7 | $235,861 |
| Biogen | 4 | $149,543 |
| Hoffmann-la Roche Limited | 12 | $132,305 |
| Sunovion Pharmaceuticals Inc. | 80 | $127,885 |
| GW Research Limited | 20 | $74,374 |
| Eisai Inc. | 15 | $58,370 |
| GSK | 16 | $48,080 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $46,772 |
| Corcept Therapeutics | 7 | $20,070 |
| Vanda Pharmaceuticals Inc. | 3 | $11,200 |
| Neurocrine Biosciences, Inc. | 1 | $9,500 |
| Jazz Pharmaceuticals Inc. | 5 | $8,950 |
| Sumitomo Pharma America, Inc. | 5 | $8,286 |
| Boehringer Ingelheim RCV GmbH & Co KG | 20 | $7,781 |
| Boehringer Ingelheim International GmbH | 39 | $7,054 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 6 | $2,449 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,016 |
How this compares
$15,516,292 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in San Diego
- Charmaine SemeniukSan Diego$8.9M
- Jonathan MeyerSan Diego$2.3M
- Vishaal MehraSan Diego$1M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.